Document is current
Any future updates will be listed below
-
Authors
Whalen, Kerry A https://orcid.org/0000-0001-8003-0346
Henry, Catherine C
Mehta, Naveen K
Rakhra, Kavya
Yalcin, Safak
Meetze, Kristan
Gibson, Neil W
Baeuerle, Patrick A
Michaelson, Jennifer S
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05117476 at ClinicalTrials.govnct05117476 at ClinicalTrials.govDocuments that mention this clinical trial
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity
https://doi.org/10.1136/jitc-2024-008987
Novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer models
https://doi.org/10.1136/jitc-2024-009867
1395 CLN 619 a clinical stage MICA B specific IgG1 antibody which restores the MICA B-NKG2D axis requires Fc function for potent anti-tumor activity
https://doi.org/10.1136/jitc-2022-sitc2022.1395
Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.
https://doi.org/10.1200/jco.2024.42.16_suppl.2588
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.2532
195 Pharmacodynamic activities of the anti-MICA/B monoclonal antibody CLN-619, evaluated as a monotherapy, support the proposed mechanisms of action and correlate with response
https://doi.org/10.1136/jitc-2024-sitc2024.0195
194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial
https://doi.org/10.1136/jitc-2023-sitc2023.0194
nct05117476 at ClinicalTrials.govDocuments that mention this clinical trial
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity
https://doi.org/10.1136/jitc-2024-008987
Novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer models
https://doi.org/10.1136/jitc-2024-009867
1395 CLN 619 a clinical stage MICA B specific IgG1 antibody which restores the MICA B-NKG2D axis requires Fc function for potent anti-tumor activity
https://doi.org/10.1136/jitc-2022-sitc2022.1395
Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.
https://doi.org/10.1200/jco.2024.42.16_suppl.2588
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.2532
195 Pharmacodynamic activities of the anti-MICA/B monoclonal antibody CLN-619, evaluated as a monotherapy, support the proposed mechanisms of action and correlate with response
https://doi.org/10.1136/jitc-2024-sitc2024.0195
194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial
https://doi.org/10.1136/jitc-2023-sitc2023.0194
Documents that mention this clinical trial
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity
https://doi.org/10.1136/jitc-2024-008987
Novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer models
https://doi.org/10.1136/jitc-2024-009867
1395 CLN 619 a clinical stage MICA B specific IgG1 antibody which restores the MICA B-NKG2D axis requires Fc function for potent anti-tumor activity
https://doi.org/10.1136/jitc-2022-sitc2022.1395
Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.
https://doi.org/10.1200/jco.2024.42.16_suppl.2588
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.2532
195 Pharmacodynamic activities of the anti-MICA/B monoclonal antibody CLN-619, evaluated as a monotherapy, support the proposed mechanisms of action and correlate with response
https://doi.org/10.1136/jitc-2024-sitc2024.0195
194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial
https://doi.org/10.1136/jitc-2023-sitc2023.0194
- License Information
